دورية أكاديمية
أعرض في EDS

Management of Hypertension in Diabetic Kidney Disease.

التفاصيل البيبلوغرافية
العنوان: Management of Hypertension in Diabetic Kidney Disease.
المؤلفون: Colbert GB; Division of Nephrology, Texas A&M University College of Medicine at Dallas, Dallas, TX 75246, USA., Elrggal ME; Kidney and Urology Center, Alexandria 21922, Egypt., Gaddy A; Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Madariaga HM; Lahey Hospital & Medical Center, Burlington, MA 01805, USA., Lerma EV; Section of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
المصدر: Journal of clinical medicine [J Clin Med] 2023 Oct 31; Vol. 12 (21). Date of Electronic Publication: 2023 Oct 31.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2012]-
مستخلص: Hypertension is a critical component of cardiovascular disease progression in patients with chronic kidney disease, and specifically diabetic kidney disease (DKD). Causation versus correlation remains up for debate, but what has been confirmed is the delay of DKD progression when hypertension is controlled or moved to guideline drive ranges. Many medications have been studied and used in real world experience for best outcomes, and we discuss below the proven winners thus far making up the renin angiotensin aldosterone system. As well, we discuss guideline changing medications including sodium-glucose cotransporter 2 inhibitors and newer generation mineralocorticoid receptor antagonists. With the growing prevalence of diabetes and DKD in the population, newer agents are emerging in multiple drug class and will be highlighted below. Clinicians continue to search for the optimal care plans for this challenging patient population.
References: Lancet. 2016 Mar 5;387(10022):957-967. (PMID: 26724178)
Circulation. 2022 May 3;145(18):e895-e1032. (PMID: 35363499)
Am J Hypertens. 2020 Dec 31;33(12):1092-1101. (PMID: 32369546)
Am J Nephrol. 2021;52(8):642-652. (PMID: 34111864)
Annu Rev Physiol. 2021 Feb 10;83:503-528. (PMID: 33197224)
Nephrol Dial Transplant. 2023 Aug 25;:. (PMID: 37632201)
BMC Nephrol. 2022 Apr 28;23(1):161. (PMID: 35484505)
N Engl J Med. 2008 Apr 10;358(15):1547-59. (PMID: 18378520)
N Engl J Med. 2015 Jan 15;372(3):211-21. (PMID: 25415805)
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006257. (PMID: 17054288)
N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
Diabetes Care. 2015 Mar;38(3):420-8. (PMID: 25271206)
N Engl J Med. 2020 Oct 8;383(15):1436-1446. (PMID: 32970396)
N Engl J Med. 2003 Apr 3;348(14):1309-21. (PMID: 12668699)
J Clin Invest. 2014 Feb;124(2):499-508. (PMID: 24463454)
BMC Nephrol. 2016 Sep 08;17(1):127. (PMID: 27609359)
J Am Soc Nephrol. 2005 Oct;16(10):3027-37. (PMID: 16120823)
Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. (PMID: 36651820)
Diabetes Care. 2017 May;40(5):632-639. (PMID: 28289041)
N Engl J Med. 2001 Sep 20;345(12):851-60. (PMID: 11565517)
Lancet. 2015 Nov 21;386(10008):2059-2068. (PMID: 26414968)
N Engl J Med. 2022 Dec 1;387(22):2021-2032. (PMID: 36326117)
J Hypertens. 2023 Dec 1;41(12):1874-2071. (PMID: 37345492)
Lancet Diabetes Endocrinol. 2016 Mar;4(3):211-220. (PMID: 26620248)
Circulation. 2019 Apr 30;139(18):2098-2109. (PMID: 30786754)
N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
Am J Kidney Dis. 2016 May;67(5):728-41. (PMID: 26597926)
Lancet. 1997 Jun 28;349(9069):1857-63. (PMID: 9217756)
N Engl J Med. 2001 Sep 20;345(12):861-9. (PMID: 11565518)
Curr Opin Cardiol. 2021 Jul 1;36(4):420-428. (PMID: 34059610)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
Arch Intern Med. 2003 Jul 14;163(13):1555-65. (PMID: 12860578)
Vasc Health Risk Manag. 2016 Oct 27;12:393-405. (PMID: 27822054)
N Engl J Med. 2011 Jan 6;364(1):11-21. (PMID: 21073363)
Nephrol Dial Transplant. 2000 Oct;15(10):1535-46. (PMID: 11007820)
Circulation. 2019 Apr 30;139(18):2089-2097. (PMID: 30586745)
J Am Soc Nephrol. 2022 Aug;33(8):1569-1580. (PMID: 35440501)
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. (PMID: 31110051)
J Am Soc Nephrol. 2015 Jan;26(1):220-9. (PMID: 24970885)
N Engl J Med. 1993 Nov 11;329(20):1456-62. (PMID: 8413456)
N Engl J Med. 2020 Dec 03;383(23):2219-2229. (PMID: 33264825)
Kidney Int. 2020 Sep;98(3):579-589. (PMID: 32739206)
Kidney Int. 2004 Jun;65(6):1991-2002. (PMID: 15149313)
N Engl J Med. 2021 Dec 9;385(24):2252-2263. (PMID: 34449181)
Am J Hypertens. 2020 Mar 13;33(3):207-213. (PMID: 31541572)
Diabetes Obes Metab. 2018 Mar;20(3):479-487. (PMID: 29024278)
Am J Kidney Dis. 2022 Aug;80(2):164-173.e1. (PMID: 35085685)
Lancet. 2000 Jan 22;355(9200):253-9. (PMID: 10675071)
N Engl J Med. 2013 Nov 14;369(20):1892-903. (PMID: 24206457)
Diabetes. 2007 Jan;56(1):8-15. (PMID: 17192459)
Am J Physiol Renal Physiol. 2022 Jun 1;322(6):F692-F707. (PMID: 35466690)
Kidney Int. 2017 Mar;91(3):683-690. (PMID: 27927602)
Kidney Int. 2020 Sep;98(3):708-716. (PMID: 32454124)
Ann Intern Med. 2001 Jul 17;135(2):73-87. (PMID: 11453706)
Diabetes Care. 2022 Dec 1;45(12):3075-3090. (PMID: 36189689)
Ann Intern Med. 2001 Apr 17;134(8):629-36. (PMID: 11304102)
Diab Vasc Dis Res. 2020 May-Jun;17(5):1479164120953625. (PMID: 32981346)
J Am Soc Nephrol. 2022 Jan;33(1):225-237. (PMID: 34732509)
Saudi J Kidney Dis Transpl. 2016 Nov-Dec;27(6):1103-1113. (PMID: 27900954)
Kidney Int. 2021 Mar;99(3S):S1-S87. (PMID: 33637192)
JACC Basic Transl Sci. 2020 Jan 29;5(2):169-179. (PMID: 32140623)
فهرسة مساهمة: Keywords: RAASi; SGTL2i; aldosterone; hypertension; mineralocorticoid receptor antagonist
تواريخ الأحداث: Date Created: 20231114 Latest Revision: 20231117
رمز التحديث: 20231117
مُعرف محوري في PubMed: PMC10648605
DOI: 10.3390/jcm12216868
PMID: 37959333
قاعدة البيانات: MEDLINE
الوصف
تدمد:2077-0383
DOI:10.3390/jcm12216868